From: GVHD-derived plasma as a priming strategy of mesenchymal stem cells
GvHD classification | Sample | Age | Sex | Diagnosis | SCT source | GvHD affected organ/score | GvHD prophylaxis |
---|---|---|---|---|---|---|---|
Acute | GA1 | 14 | M | AA | BM | Skin I | SIRO + MMF |
GA2 | 10 | F | ALL | BM | Skin III | SIRO + MMF | |
GA3 | 44 | F | AA | BM | Eyes I/mouth I | – | |
GA4 | 30 | F | B-ALL | BM | Mouth I/liver I | SIRO | |
GA5 | 19 | M | ALL | BM | Skin/liverb | Prednisone | |
GA6 | 21 | M | AA/PNH+ | BM | Skin IV/liver/GIb | Prednisone + MMF | |
GA7 | 12 | M | B-ALL | BM | Skin III | CSA | |
Chronic | GC1 | 26 | M | BAL/MRD+ | BM | Mild | – |
GC2 | 36 | M | CML | BM | Mild | – | |
GC3 | 52 | F | AML | PBSC | – | CSA + prednisone | |
GC4 | 41 | F | BAL/MRD+ | PBSC | Moderate | CSA | |
GC5 | 50 | F | CML | BM | – | CSA | |
GC6 | 43 | M | CML | PBSC | Moderate | CSA + prednisone | |
GC7 | 12 | M | ALL | BM | Mild | – | |
GC8 | 24 | F | AML | PBSC | Mild | – | |
GC9 | 70 | M | AML | BM | Mild | CSA | |
GC10 | 69 | M | AML | BM | Severe | CSA | |
GC11a | 61 | M | Myelofibrosis | PBSC | Moderate | CSA + MMF | |
GC12 | 43 | M | CML | PBSC | Severe | – |